Strategic area of application
Gastro-enterology - Infectiology - Parasitology - Oncology
Therapeutics, Pharma or Biotech
Cell Therapy - cell biology - Biobanking - Drug delivery device - services
Presentation of company's activity
MaaT Pharma™ is a biotechnology company created to treat important diseases, using the power of gut microbial ecology.
MaaT stands for Microbiota as a Therapy and focuses on using the clinical promises of faecal microbiotherapy (also known as Fecal Microbiota Transplant) to develop innovative solutions of clinical relevance to treat unmet medical needs of dysbiosis-related diseases.
Our company has been co-founded in 2014, in France, by a well-balanced team made of scientists, entrepreneurs and scientific partners including INRA transfer as well as Seventure as a financial partner.
The team's intention is to embrace a societal project designed to deeply change our contemporary medical field.
Breakthrough strategy aiming at transforming the faecal microbiotherapy into a commodity to hospital clinicians
Skills and know-how
Healthcare operation management
Product pipeline 1
Therapeutic indication: Dysbiotic enteropathies
Presentation of company's services
MaaT Pharma proposes to correct treatment-induced dysbiosis by delivering a drug aiming at restoring a balanced intestinal ecosystem. Our initial focus will be on providing a Platform for safe (autologous; qualified inoculum) and cost effective microbiota restoration made of two main products: MaaT001 (Innovative live frozen inoculum suspension) and MaaT002 (Innovative device for stool collection and storage, convenient for duodenal and rectal administration). The technology to develop the products is based on the know-how of co-founders as well as know-how from the INRA (French National Institute specialized in microbiology and metagenomics).
Presentation of company's technologies
MaaT Pharma technology is based on a private GMP Platform allowing to manage fecal transplantation from sample collection up to its implantation in the patient. MaaT Pharma is also developing a medical device to support its process and to guarantee the optimal efficacy of the treatment combined with a very good safety for the manufacturer's employees. The autologous approach of MaaT Pharma allows a safer approach than the current allogenic technology. In addision, the good recognition of the autologous transplant by the human body let expected a very broad number of therapeutic area from infectious disease to immunology and inflammatory diseases.